Radio-responsive gene therapy for malignant glioma cells without the radiosensitive promoter: Caspase-3 gene therapy combined with radiation

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 318-323

  Tsurushima, Hideo ^a   Yuan, Xuan ^b   Dillehay, Larry E ^b   Leong, Kam W ^a  

^a Johns Hopkins University   (United States)

^b Division of Radiation Oncology   (United States)

Author keywords

Caspase 3 gene therapy; Radiation; Radiation sensitive promoter; Radio responsive gene therapy

Indexed keywords

CASPASE 3; EARLY GROWTH RESPONSE FACTOR 1;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CASPASE 3 GENE; CELL DEATH; CONTROLLED STUDY; CYTOMEGALOVIRUS; EARLY GROWTH RESPONSE GENE 1; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MULTIMODALITY CANCER THERAPY; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RADIATION RESPONSE; RADIOSENSITIVITY;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYSTEINE PROTEINASE INHIBITORS; CYTOMEGALOVIRUS; DOSE-RESPONSE RELATIONSHIP, RADIATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE THERAPY; GLIOMA; HUMANS; OLIGOPEPTIDES; PLASMIDS; PROMOTER REGIONS (GENETICS); RADIOTHERAPY; TRANSFECTION;

CYTOMEGALOVIRUS;

EID: 33845672645     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.015     Document Type: Article

References (27)

1. Chen S.H., Shine H.D., Goodman J.C., Grossman R.G., and Woo S.L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl Acad. Sci. USA 91 (1994) 3054-3057
2. O'Malley B.W., Chen S.H., Schwartz M.R., and Woo S.L. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55 (1995) 1080-1085
3. van der Eb M.M., Cramer S.J., Vergouwe Y., Schagen F.H., van Kriekem J.H., van der Eb A.J., et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. 5 (1998) 451-458
4. Brand K., Loser P., Arnold W., Bartels T., and Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther. 5 (1998) 1363-1371
5. Weichselbaum R.R., Hallahan D.E., Beckett M.A., Mauceri H.J., Lee H., Sukhatme V.P., and Kufe D.W. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54 (1994) 4266-4269
6. Joki T., Nakamura M., and Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum. Gene Ther. 6 (1995) 1507-1513
7. Koga S., Hirohata S., Kondo Y., Komata T., Takakura K., Inoue M., et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 11 (2000) 1397-1406
8. Arbuthnot P.B., Bralet M.P., Le Jossic C., Dedieu J.F., Perricaudet M., Brechot C., and Ferry N. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum. Gene Ther. 7 (1996) 1503-1514
9. Datta R., Rubin E., Sukhatme V., Qureshi S., Hallahan D., Weichselbaum R.R., and Kufe D.W. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc. Natl Acad. Sci. USA 89 (1992) 10149-10153
10. Fan L., Freeman K.W., Khan T., Pham E., and Spencer D.M. Improved artificial death switches based on caspase and FADD. Hum. Gene Ther. 10 (1999) 2273-2285
11. Sakamoto K.M., Bardeleben C., Yates K.E., Raines M.A., Golde D.W., and Gasson J.C. 5′upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 6 (1991) 867-871
12. Marples B., Scott S.D., Hendry J.H., Embleton M.J., Lashford L.S., and Margison G.P. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 7 (2000) 511-517
13. Liu S.Q., Saijo K., Todoroki T., and Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sections. Nat. Med. 1 (1995) 267-271
14. Fernandes-Alnemri T., Liwack G., and Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem. 269 (1994) 30761-30766
15. Tewari M., Qian L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., and Poirier G.G. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81 (1995) 801-809
16. Nicolson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 37-43
17. Martin S.J., and Green D.R. Protease activation during apoptosis: death by a thousand cuts?. Cell 82 (1995) 349-352
18. Yamabe K., Shimizu S., Ito T., Yoshioka Y., Nomura M., Narita M., et al. Cancer gene therapy using a pro-apoptotic gene caspase-3. Gene Ther. 6 (1999) 1952-1959
19. Shinohara N., Nuramatsu Y., Yoshida Y., Asai A., Kirino T., and Hamada H. Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Exp. Cell Res. 256 (2000) 423-433
20. Colussi P.A., Harvey N.L., Shearwin-Whyatt L.M., and Kumar S.J. Conversion of procaspase-3 to an autoactivating caspase by fusion to the caspase-2 prodomain. J. Biol. Chem. 273 (1998) 26566-26570
21. Theh B.S., Aguilar-Cordova E., Vlachaki M.T., Aguilar L., Mai W.Y., Caillouet J., et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 7 (2002) 458-466
22. Manome Y., Kunieda T., Wen P.Y., Koga T., Kufe D.W., and Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum. Gene Ther. 9 (1998) 1409-1417
23. Kawashita Y., Ohtsuru A., Kaneda Y., Nagayama Y., Kawazoe Y., Eguchi S., et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10 (1999) 1509-1519
24. Kuerbitz S., Plunkett B., Walsh W., and Kastan M. Wild-type p53 is a cell cycle checkpoint determinant following radiation. Nature 89 (1992) 7491-7495
25. Rogulski K.R., Freytag S.O., Zhang K., Gilbert J.D., Paielli D.L., Kim J.H., et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60 (2000) 1193-1196
26. Wakasa T., Inoue T., Kawai N., Murakami J., Kishi K., and Fukui K. The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. Br. J. Radiol. 75 (2002) 657-662
27. Asai A., Miyagi Y., Sugiyama A., Gamanuma M., Hong S.H., Takamoto S., et al. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol. 19 (1994) 259-268